BURLINGTON, Mass., April 24, 2014 /PRNewswire/ -- Decision Resources Group finds that at six months post-launch in the United States, 49 percent of surveyed U.S. medical oncologists have prescribed Boehringer Ingelheim's irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) Gilotrif, for NSCLC patients outside of clinical trials. Among current non-prescribers of Gilotrif, just over half expects to prescribe Gilotrif to their EGFR-mutation-positive NSCLC patients within the next three months.
Over one-half of surveyed medical oncologists reported high favorability towards Gilotrif, and nearly two-thirds indicated a high interest level in learning more about the product.
The majority of Gilotrif's use to date has been in EGFR TKI-naive patients, most commonly in the first-line but also in the second- and third-lines. Surveyed Gilotrif prescribers predicted that uptake of Gilotrif will continue to increase in the next six months.
Surveyed medical oncologists most frequently cited Gilotrif's efficacy benefit as its greatest perceived advantage. In contrast, Gilotrif's safety and tolerability profiles and managed care issues are most frequently cited by surveyed oncologists as key disadvantages.
Surveyed medical oncologists perceive the price, availability of other EGFR TKIs and lack of familiarity with Gilotrif to be the three main factors holding back wider use of Gilotrif in treatment-naive, EGFR-mutation-positive NSCLC patients.
Comments from Decision Resources Group Analyst Jennifer Bamford:
"Gilotrif's patient share remains minimal for the treatment of first-line EGFR-mutation-positive NSCLC patients, reaching only 6 percent at six months post-launch, demonstrating that Gilotrif still fails to significantly differentiate itself from Tarceva (Genentech/Roche/Chugai/Astellas)."
"At six months post-launch, surveyed medical oncologists remain moderately to highly interested in prescribing Gilotrif in new patient populations and hope to see regulatory approval for the EGFR mutation-positive, EGFR TKI pretreated patient population and for patients harboring other EGFR mutations, including those associated with resistance to Tarceva (e.g. T790M mutations)."
About Decision Resources Group
Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. Clients rely on this analysis and data to make informed decisions. Find out more at www.DecisionResourcesGroup.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.